Prosecution Insights
Last updated: April 19, 2026

Examiner: SEAMAN, D MARGARET M

Tech Center 1600 • Art Units: 1625 1629 1691

This examiner grants 77% of resolved cases

Performance Statistics

76.6%
Allow Rate
+16.6% vs TC avg
1407
Total Applications
+7.9%
Interview Lift
862
Avg Prosecution Days
Based on 1387 resolved cases, 2023–2026

Rejection Statute Breakdown

3.7%
§101 Eligibility
24.3%
§102 Novelty
15.1%
§103 Obviousness
33.9%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18030686 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS Non-Final OA The Regents of the University of California
18551033 NEW PROCESS FOR THE SYNTHESIS OF 5-{5-CHLORO-2-[(3S)-3-[(MORPHOLIN-4-YL)METHYL]-3,4-DIHYDROISOQUINOLINE-2(1H)- CARBONYL]PHENYL}-1,2-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID DERIVATIVES AND ITS APPLICATION FOR THE PRODUCTION OF PHARMACEUTICAL COMPOUNDS Non-Final OA NOVARTIS AG
17962656 Toll-Like Receptor 8 (TLR8)-Specific Antagonists and Methods of Making and Uses Thereof Non-Final OA The Regents of the University of Colorado, a body corporate
18034439 PROCESS FOR THE PREPARATION OF HETEROARYL-SUBSTITUTED SULFUR(VI) COMPOUNDS Non-Final OA H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
18041184 PROTEASOME ENHANCERS AND USES THEREOF Non-Final OA Board of Trustees of Michigan State University
18576580 FUNGICIDAL USE Non-Final OA Adama Makhteshim Ltd.
17576923 PRODRUG COMPOSITIONS AND METHODS OF TREATMENT Non-Final OA AQUESTIVE THERAPEUTICS, INC.
18288318 PURINE NUCLEOSIDES, THEIR INTERMEDIATES, AND METHODS OF PREPARATION THEREOF Non-Final OA The U.S.A., as Represented by the Secretary, Department of Health and Human Services
18256680 A TAUTOMERIC LIGAND ENABLES BIOMIMETIC C-H HYDROXYLATION WITH MOLECULAR OXYGEN Final Rejection THE SCRIPPS RESEARCH INSTITUTE
18259696 HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF Non-Final OA VORONOI INC.
18043971 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)-1-(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE Non-Final OA LOXO ONCOLOGY, INC.
17297269 DILTIAZEM HYDROCHLORIDE AND PREGABALIN COMPOSITION, METHOD FOR PREPARING THE SAME, AND USAGE THEREOF Non-Final OA HAINAN JIN RUI PHARMACEUTICAL CO., LTD.
17917891 INJECTABLE MELATONIN COMPOSITION FOR THE TREATMENT OF VIRAL DISEASES Non-Final OA UNIVERSIDAD DE GRANADA
18264994 NOVEL COMPOUNDS COMPRISING A NEW CLASS OF TRANSTHYRETIN LIGANDS FOR TREATMENT OF COMMON AGE-RELATED COMORBIDITIES Non-Final OA RAJA, Arun
18355983 KETAMINE COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM Non-Final OA Zevra Therapeutics, Inc.
18340054 USE OF FUBP1 INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION Non-Final OA INSERM - INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE
18308288 INHIBITORS OF ENPP1 AND MODULATION OF BONE GROWTH Non-Final OA Petragen, Inc.
18040868 AN IMPROVED HIGHLY EFFICIENT PROCESS FOR THE PREPARATION OF NINTEDANIB AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Non-Final OA BDR LIFESCIENCES PRIVATE LIMITED
17758384 PREPARATION METHOD OF A HIGH-OPTICAL-PURITY CHIRAL OXO-AZA-CYCLOALKANE COMPOUND Non-Final OA XIN FA PHARMACEUTICAL CO., LTD.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month